Thermo Fisher Scientific Inc. teamed up with Moderna, Inc. for the production of Spikevax, COVID-19 vaccine, and other investigational mRNA therapies in its pipeline and provide devoted capacity for lyophilized and liquid filling, among other aseptic fill-finish services.
Merck acquired AmpTec, to enhance its capacity to create and manufacture mRNA for its clients for use in many other diseases-related vaccines, therapies, and diagnostics and to hasten the creation of new treatments for numerous more ailments.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5339
Published Date: Oct 20, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The increasing production of vaccines and the rising need for insect-derived products are the major factors driving the growth of the market.
The market size of insect cell lines is anticipated to attain a CAGR of 12% over the forecast period, i.e., 2024 - 2036.
The major players in the market are Sigma-Aldrich Corporation, GE Healthcare Technologies Inc., Lonza Group, Becton, Dickinson & Company, HiMedia Laboratories LLC, Takara Bio Inc., CellGenix GmbH, Atlanta Biologicals Inc., PromoCell GmbH.
The high five segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.